Weird feeling of danger and it's not just the Bear. Vegas just does not sound good. NYC is just empty still. California is close to a lock down. Marlin players now have endangered the whole return to sports idea.
Obviously Draftkings is getting slammed! This is worrisome for football... But in a weird way good for the overall stock market! No sports means stocks are the only action in town outside of virtual poker and virtual 21 and such...
INOV-
Description
Inovalon Holdings, Inc. provides cloud-based platforms for data-driven healthcare. It operates Inovalon ONE Platform, a cloud-based platform that interconnect with the healthcare ecosystem to aggregate and analyze data in real-time, as well as empowers the application in resulting insights. The company also operates myABILITY software platform, an integrated set of cloud-based applications for providers that offers connectivity, administrative, clinical and quality analysis, management, and performance improvement capabilities to acute, post-acute, and ambulatory point-of-care provider facilities.
Fair enough until last week they were considered third in their field... But they landed a big Walmat contract which caught my eye.
& I do need a health providing kind of stock... It went $20-$22. Retraced to $21 Fri and is now broaching that high- Close to a YTD break out. This looks like a winner.
ABUS-
Arbutus Biopharma has for some years owned the rights to a technology that can be used to deliver messenger RNA to a patient's cells. Back in January 2019,
Moderna (
NASDAQ:MRNA), whose entire drug platform is based upon messenger RNA, filed a petition with the U.S. Patent Office to have the small biotech firm's drug-delivery patent declared invalid.
Instead, on Thursday, the agency's Patent Trial and Appeal Board ruled in favor of Arbutus.<--
The ruling is important as Moderna's COVID-19 vaccine candidate uses technology that's covered by this patent. The experimental vaccines that the company is developing use mRNA to issue instructions to the body's cells to start manufacturing proteins that will trigger an immune system response. But a major issue with this method is the matter of treatment delivery -- how to get these instructions into the body's cells. Several years ago, Moderna licensed its delivery technology -- the use of lipid nanoparticles -- from a small Canadian company called Acuitas. That company, it turns out, had licensed its technology from Arbutus Biopharma -- and it did not have rights to sublicense it.<---- Wooooooo.
What could this mean for ABUS if the vax hits? > Is there a sliding scale here... a % ?
Conflicting analyst thoughts-))
-Arbutus Biopharma
upside priced in, Baird downgrades to Neutral 07:38 ABUS, MRNA As reported earlier, Baird analyst Madhu Kumar downgraded Arbutus Biopharma (ABUS) to Neutral from Outperform with a $4 price target. The analyst believes its positive court ruling against Moderna (MRNA) has been already priced in and with its substantial move yesterday, upside is limited.
The thing is the stock spiked all the way to $7 last week! from like $3 so I'm thinking this has more to go-$5 area currently )))
Today+ Arbutus Biopharma
price target raised to $8 from $6 at B. Riley FBR 08:52 ABUS B. Riley FBR analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow.
Lost in the mix is the devastating news about Ann Taylor- This is part of that " danger " feeling...
Ascena Retail Group Inc. — corporate parent of Ann Taylor, Lane Bryant and other chains — filed for Chapter 11 bankruptcy protection. The company said Thursday its restructuring plan will allow it to reduce its debt by $1 billion. It also will close an unspecified number of stores across all of its major banners, including shuttering all of its Catherines plus-size apparel locations.
Ascena’s bankruptcy is the scariest yet for the industry in the Covid-19 era, because the company’s collapse has the potential to create more devastating ripple effects than were caused by almost any of the other retail washouts that preceded it.
Ascena had nearly
2,800 stores as of February, a staggeringly large portfolio that includes Loft and kids’ shop Justice. That makes it a highly important tenant for many mall operators. The company accounted for 4.7% of annualized base rent at Tanger Factory Outlet Centers Inc., according to that operator’s latest quarterly filing, a share that makes Ascena its second-largest tenant behind only Gap Inc. For Simon Property Group Inc., only Gap and Victoria’s Secret parent L Brands Inc. account for a greater share of annual base rent than Ascena. It is in the top 10 for Brookfield Property Partners and Acadia Realty Trust.<----- Hummmm
Still looking for shorts Van...?
Ascena has not detailed exactly how many stores it will close. It committed to closing all of its Catherines outposts, which numbered almost 300 as of February. It said it will shutter a “significant” portion of its more than 800 Justice stores, and a “select” number of its Ann Taylor, Loft, Lane Bryant and Lou & Grey locations-- Ann Taylor and Justice stores are fixtures in traditional malls; Lane Bryant and Catherines chains are often in strip-shopping centers. Loft stores are found in mixed-use developments, while factory outposts of the Ann Taylor and Loft brands are mainstays in outlet malls. That means a wider variety of chains count it as a co-tenant and could feel pain from being next to an empty storefront. <-- ripple effect